#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Vitamin D in relation to head and neck cancer


Authors: David Kalfeřt 1;  Marie Ludvíková 2;  Martin Pešta 2;  Ondřej Topolčan 3
Authors‘ workplace: Klinika otorinolaryngologie a chirurgie hlavy a krku LF UK a FN Hradec Králové, přednosta prof. MUDr. Viktor Chrobok, CSc., Ph. D. 1;  Ústav biologie LF UK Plzeň, vedoucí RNDr. Martin Pešta, Ph. D. 2;  Laboratoř imunochemické diagnostiky, oddělení nukleární medicíny LF UK a FN Plzeň, vedoucí prof. MUDr. Ondřej Topolčan, DrSc. 3
Published in: Vnitř Lék 2014; 60(1): 51-58
Category: Reviews

Overview

Vitamin D was lately introduced as the important anti-cancer agent with therapeutic potential to be used in prevention and therapy of malignant tumors. Head and neck squamous cell cancer (HNSCC) is the sixth most common cancer in the world. Prognosis of this cancer is in most patients poor. In attempts to improve therapy of this cancer, contemporary research is focused on extension of the etiological and pathobiological aspects of cancerogenesis of HNSCC. This fact provoked us to summarize present scientific knowledge about etiopathological, chemopreventive and therapeutic role of vitamin D in head and neck squamous cancer and outline the direction of further research in this interesting and from clinical point of view important field.

Key words:
head and neck squamous cell carcinoma – anti-tumor effect – vitamin D


Sources

1. Matějovská Kubešová H, Tůmová J, Polcarová V et al. Vitamin D – připomínka známých a přehled méně známých skutečností. Vnitř Lék 2012; 58(3): 196–201.

2. Chiang KC, Chen TC. The Anti-cancer Actions of Vitamin D. Anticancer Agents Med Chem 2013; 13(1): 126–139.

3. Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer 2013; 133(9): 2013–2023. 

4. Barnes L (eds). Surgical pathology of the head and neck. 3 ed. New York: Informa Healthcare 2008. ISBN 9780849390234.

5. ÚZIS ČR. Novotvary 2010 ČR. Dostupné z WWW: <http://www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/novotvary>.

6. Barnes L, Eveson JW, Reichart P et al. Pathology and genetics of head and neck tumours. WHO classification of tumours series. IARC Press: Lyon 2005.

7. Ludvíková M, Pešta M, Holubec L jr. et al. Nové aspekty patobiologie nádorů. Česk Patol 2009; 45(4): 94–99.

8. Kalfeřt D, Ludvíková M. Nádorové markery u dlaždicových karcinomů hlavy a krku. Onkologie 2012; 6(5): 241–246.

9. Meyer F, Liu G, Douville P et al. Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients. Int J Cancer 2011; 128(7): 1741–1746.

10. Orell-Kotikangas H, Schwab U, Österlund P et al. High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head Neck 2012; 34(10): 1450–1455.

11. Kulda V. Metabolizmus vitaminu D. Vnitř Lék 2012; 58(5): 400–404.

12. Drábová K, Bienertová Vašků J, Lokaj P et al. Vitamin D – jeho fyziologie, patofyziologie a význam v etiopatogenezi nádorových onemocnění. Čas Lék Česk 2013; 152(1): 20–30.

13. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985; 76(4): 1536–1538.

14. Azad AK, Bairati I, Qiu X et al. Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. Int J Cancer 2013; 132(11): 2520–2527.

15. Pešta M. Polymorfizmus genu pro receptor vitaminu D. Vnitř Lék 2012; 58(5): 381–385.

16. Chakraborti CK. Vitamin D as a promising anticancer agent. Indian J Pharmacol 2011; 43(2): 113–120.

17. Maruyama R, Aoki F, Toyota M et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 2006; 66(9): 4574–4583.

18. Wagner N, Wagner KD, Schley G et al. 1,25-dihydroxyvitamin D3-induced apoptosis of retinoblastoma cells is associated with reciprocal changes of Bcl-2 and bax. Exp Eye Res 2003; 77(1): 1–9.

19. Köstner K, Denzer N, Müller CS et al. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29: 3511–3536.

20. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29(9): 308–311.

21. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911–1930.

22. Ross AC, Taylor CL, Yaktine AL et al. Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press: Washington 2011.

23. Pilz S, Tomaschitz A, Obermayer-Pietsch B et al. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res 2009; 29(9): 3699–3704.

24. Rosen CJ, Abrams SA, Aloia JF et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012; 97(4): 1146–1152.

25. Robsahm TE, Tretli S, Dahlback A et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 2004; 15(2): 149–158.

26. Zhou W, Heist RS, Liu G et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 2007; 25(5): 479–485.

27. Buttigliero C, Monagheddu C, Petroni P et al. Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist 2011; 16(9): 1215–1227.

28. Goodwin PJ, Ennis M, Pritchard KI et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27(23): 3757–3763.

29. Lipworth L, Rossi M, McLaughlin JK et al. Dietary vitamin D and cancers of the oral cavity and esophagus. Ann Oncol 2009; 20(9): 1576–1581.

30. Gugatschka M, Kiesler K, Obermayer-Pietsch B et al. Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Arch Otorhinolaryngol 2011; 268(8): 1201–1204.

31. Arem H, Weinstein SJ, Horst RL et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev 2011; 20(6): 1178–1184.

32. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem 2013; 59(5): 771–780.

33. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr 1999; 53(12): 920–926.

34. Ahn J, Yu K, Stolzenberg-Solomon R et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19(13): 2739–2745.

35. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376(9736): 180–188.

36. Hama T, Norizoe C, Suga H et al. Prognostic significance of vitamin D receptor polymorphisms in head and neck squamous cell carcinoma. PLoS One 2011; 6(12): 29634.

37. Srinivasan M, Parwani AV, Hershberger PA et al. Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem Mol Biol 2011; 123(1–2): 30–36.

38. Young MRI, Walker DD. Vitamin D3 and Its Role in the Treatment of Head and Neck Squamous Cell Carcinoma. In: Li X. Squamous Cell Carcinoma. Dostupné z WWW: .

39. Zamrazil V. Význam vitaminu D – nové poznatky, které svědčí o jeho úloze v medicíně. Vnitř Lék 2012; 58(5): 379–380.

40. Jiang H, Lin J, Su ZZ et al. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9(11): 3397–3406.

41. Saramäki A, Banwell CM, Campbell MJ et al. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34(2): 543–554.

42. Hager G, Formanek M, Gedlicka C et al. 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 2001; 121(1): 103–109.

43. Hager G, Kornfehl J, Knerer B et al. Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. Acta Otolaryngol 2004; 124(1): 90–96.

44. Gedlicka C, Hager G, Weissenböck M et al. 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 2006; 35(8): 472–478.

45. Lu L, Qiu J, Liu S et al. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol Cancer Ther 2008; 7(5): 1268–1274.

46. Walker DD, Reeves TD, de Costa AM et al. Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck. Cytokine 2012; 58(3): 448–454.

47. Walsh JE, Clark AM, Day TA et al. Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol 2010; 71(7): 659–665.

48. Pandit R, Lathers DM, Beal NM et al. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000; 109(8): 749–754.

49. Kulbersh JS, Day TA, Gillespie MB et al. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol Head Neck Surg 2009; 140(2): 235–240.

50. Šterzl I. D vitamin a imunita. Vnitř Lék 2012; 58(5): 405–410.

51. Pries R, Wollenberg B. Cytokine in head and neck cancer. Cytokine Growth Factor Rev 2006; 17(3): 141–146.

52. Sporn MB, Dunlop NM, Newton DL et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976; 35(6): 1332–1338.

53. Meier JD, Enepekides DJ, Poirier B et al. Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. Arch Otolaryngol Head Neck Surg 2007; 133(11): 1149–1152.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#